Trough concentrations of cyclosporine in blood following administration with grapefruit juice
- PMID:12959294
- PMCID: PMC1364619
- DOI: 10.1111/j.1365-2125.1993.tb00395.x
Trough concentrations of cyclosporine in blood following administration with grapefruit juice
Abstract
Components of grapefruit juice have been shown to inhibit CYP3A4 activity, the enzyme involved in cyclosporine metabolism. Eleven medically stable patients (seven males, four females) receiving cyclosporine following kidney transplantation were instructed to take their usual dose of cyclosporine with water for 1 week (Phase 1), with grapefruit juice (8 ounces) for 1 week (Phase 2) and again with water for 1 week (Phase 3). Trough blood samples were obtained at the end of each phase for measurement of cyclosporine concentration using a specific monoclonal whole blood radioimmunoassay. Cyclosporine trough concentrations averaged 116.9 +/- 51.6 ng ml(-1) in the first phase, 145.3 +/- 44.7 ng ml(-1) with grapefruit juice (P < 0.05 compared with the first and third phases) and 111.2 +/- 56.1 ng ml(-1) in the third phase. Cyclosporine concentrations increased in 8 of 11 patients when given with grapefruit juice (mean increase 32%; range -4 to 97%) and declined in 10 of 11 when subjects resumed taking cyclosporine with water (mean decrease 27%). These results suggest that grapefruit juice increases trough concentrations of cyclosporine in blood, possibly by inhibiting pre-hepatic gut wall metabolism, and could be useful in optimizing therapy with this drug.
Similar articles
- 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P.Edwards DJ, et al.Clin Pharmacol Ther. 1999 Mar;65(3):237-44. doi: 10.1016/S0009-9236(99)70102-5.Clin Pharmacol Ther. 1999.PMID:10096255Clinical Trial.
- Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG.Min DI, et al.Transplantation. 1996 Jul 15;62(1):123-5. doi: 10.1097/00007890-199607150-00023.Transplantation. 1996.PMID:8693526Clinical Trial.
- Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.Ducharme MP, Warbasse LH, Edwards DJ.Ducharme MP, et al.Clin Pharmacol Ther. 1995 May;57(5):485-91. doi: 10.1016/0009-9236(95)90032-2.Clin Pharmacol Ther. 1995.PMID:7768070Clinical Trial.
- Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis.Sridharan K, Sivaramakrishnan G.Sridharan K, et al.Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):665-673. doi: 10.1007/s13318-016-0351-4.Eur J Drug Metab Pharmacokinet. 2016.PMID:27278683Review.
- Drug-grapefruit juice interactions.Kane GC, Lipsky JJ.Kane GC, et al.Mayo Clin Proc. 2000 Sep;75(9):933-42. doi: 10.4065/75.9.933.Mayo Clin Proc. 2000.PMID:10994829Review.
Cited by
- The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.Jones TE.Jones TE.Clin Pharmacokinet. 1997 May;32(5):357-67. doi: 10.2165/00003088-199732050-00002.Clin Pharmacokinet. 1997.PMID:9160170Review.
- Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, Sawada Y.Takanaga H, et al.Br J Clin Pharmacol. 2000 Jan;49(1):49-58. doi: 10.1046/j.1365-2125.2000.00140.x.Br J Clin Pharmacol. 2000.PMID:10606837Free PMC article.Clinical Trial.
- The influence of food on the absorption and metabolism of drugs: an update.Williams L, Hill DP Jr, Davis JA, Lowenthal DT.Williams L, et al.Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):201-11. doi: 10.1007/BF03189714.Eur J Drug Metab Pharmacokinet. 1996.PMID:8980916Review.
- Drug interactions with grapefruit juice.Ameer B, Weintraub RA.Ameer B, et al.Clin Pharmacokinet. 1997 Aug;33(2):103-21. doi: 10.2165/00003088-199733020-00003.Clin Pharmacokinet. 1997.PMID:9260034Review.
- Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Williams D, Feely J.Williams D, et al.Clin Pharmacokinet. 2002;41(5):343-70. doi: 10.2165/00003088-200241050-00003.Clin Pharmacokinet. 2002.PMID:12036392Review.
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources